维持性血液透析患者血浆转化生长因子β1检测及其临床意义

目的检测维持性血液透析(MHD)治疗患者血浆TGFβl水平并探讨其可能的临床意义。方法应用竞争性酶联免疫法(EISA)测定27例MHD患者和20例健康对照者血浆TGFβ1水平。结果与正常对照组相比，MHD患者血浆TGFβ1水平明显增加(82.9±9.8比50.2±5.7)ng/ml(P＜0.01)。但血浆TGFβl水平与血Hct无明显相关关系(r=0.152，P＞0.05)。另外，患者血浆TGFβ1水平与接受rHuEPO治疗的剂量之间亦无明显相关性。将MHD患者按血浆iPTH水平现再分小于和大于200pg/ml两组，发现两组间血浆TGFβl水平有明显统计学差异(72.1±4.6比93.7±6.5)pg/ml(P＜0.05)，但所有MHD患者血浆TGFβ1与iPTH水平之间无明显相关性(r=0.257，P＞0.05)。结论MHD患者TGFβl水平增加可能参与许多不利因素的发生，特别与继发甲状旁腺机能亢进关系密切。

DETERMINATION OF TRANSFORMING GROWIH FACTOR

Objective:To detemine transfoming growth factor βl plasma lever and investigate its clinical significance in mainte-nance hemodialysis (MHD) patients. Methods:The plasma level of TGFβ1 was measuretd by a solid phase ELISA in 27 uremic patients undergoing MHD,20 healthy control subjetts. Results: Compared with controls,the patients on MHD had significantly highermean TGFβ1 level (82.9±9. 8 vs 50.2±5.7ng/ml,P＜ 0.01). However,the mean plasma level of TGFβ1 wass not correlated witht he hematocrit(Het)(r = 0.152,P ＞ 0.05). Similarly,no correlation was observed between the plasma level of TGFβ 1 and the dose oferythropoietin (EPO) administered. The patients undergoing MHD were divided into two groups according to the serum level ofiPTH. Plasma level of TGFβ1 in patients with iPTH than 200pg/ml was significantly higher than that lower than 200pg/ml (72. 1 ±4.6 vs 93.7±6.5pg/ml,P＜ 0. 05). Nevertheless,there was no correlation between serum iPTH and the plasma level of TGF β 1(r =0. 257,P＞0.05). Conclusions:Our results show than MHD is asssociated with the increased the plasma eve of TGFβ1. Specificaly,the patients with secondary hyperparathyrodism (SHP) have more higher the plasma level of TGFβ1 than without SHP.